277 related articles for article (PubMed ID: 17724153)
1. Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
Quenelle DC; Prichard MN; Keith KA; Hruby DE; Jordan R; Painter GR; Robertson A; Kern ER
Antimicrob Agents Chemother; 2007 Nov; 51(11):4118-24. PubMed ID: 17724153
[TBL] [Abstract][Full Text] [Related]
2. ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
Berhanu A; King DS; Mosier S; Jordan R; Jones KF; Hruby DE; Grosenbach DW
Antimicrob Agents Chemother; 2009 Dec; 53(12):4999-5009. PubMed ID: 19752270
[TBL] [Abstract][Full Text] [Related]
3. Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses.
Smee DF; Sidwell RW; Kefauver D; Bray M; Huggins JW
Antimicrob Agents Chemother; 2002 May; 46(5):1329-35. PubMed ID: 11959564
[TBL] [Abstract][Full Text] [Related]
4. Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir.
Quenelle DC; Collins DJ; Wan WB; Beadle JR; Hostetler KY; Kern ER
Antimicrob Agents Chemother; 2004 Feb; 48(2):404-12. PubMed ID: 14742188
[TBL] [Abstract][Full Text] [Related]
5. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge.
Yang G; Pevear DC; Davies MH; Collett MS; Bailey T; Rippen S; Barone L; Burns C; Rhodes G; Tohan S; Huggins JW; Baker RO; Buller RL; Touchette E; Waller K; Schriewer J; Neyts J; DeClercq E; Jones K; Hruby D; Jordan R
J Virol; 2005 Oct; 79(20):13139-49. PubMed ID: 16189015
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice.
Quenelle DC; Collins DJ; Kern ER
Antimicrob Agents Chemother; 2003 Oct; 47(10):3275-80. PubMed ID: 14506041
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
Quenelle DC; Buller RM; Parker S; Keith KA; Hruby DE; Jordan R; Kern ER
Antimicrob Agents Chemother; 2007 Feb; 51(2):689-95. PubMed ID: 17116683
[TBL] [Abstract][Full Text] [Related]
8. Specific targeting of the F13L protein by ST-246 affects orthopoxvirus production differently.
Duraffour S; Vigne S; Vermeire K; Garcel A; Vanstreels E; Daelemans D; Yang G; Jordan R; Hruby DE; Crance JM; Garin D; Andrei G; Snoeck R
Antivir Ther; 2008; 13(8):977-90. PubMed ID: 19195323
[TBL] [Abstract][Full Text] [Related]
9. Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures.
Duraffour S; Snoeck R; de Vos R; van Den Oord JJ; Crance JM; Garin D; Hruby DE; Jordan R; De Clercq E; Andrei G
Antivir Ther; 2007; 12(8):1205-16. PubMed ID: 18240860
[TBL] [Abstract][Full Text] [Related]
10. In vivo imaging of cidofovir treatment of cowpox virus infection.
Goff A; Twenhafel N; Garrison A; Mucker E; Lawler J; Paragas J
Virus Res; 2007 Sep; 128(1-2):88-98. PubMed ID: 17524511
[TBL] [Abstract][Full Text] [Related]
11. Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses.
Florescu DF; Keck MA
Expert Rev Anti Infect Ther; 2014 Oct; 12(10):1171-8. PubMed ID: 25120093
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous infections of mice with vaccinia or cowpox viruses and efficacy of cidofovir.
Quenelle DC; Collins DJ; Kern ER
Antiviral Res; 2004 Jul; 63(1):33-40. PubMed ID: 15196818
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory activity of alkoxyalkyl and alkyl esters of cidofovir and cyclic cidofovir against orthopoxvirus replication in vitro.
Keith KA; Wan WB; Ciesla SL; Beadle JR; Hostetler KY; Kern ER
Antimicrob Agents Chemother; 2004 May; 48(5):1869-71. PubMed ID: 15105146
[TBL] [Abstract][Full Text] [Related]
14. Treatment of cowpox virus respiratory infections in mice with ribavirin as a single agent or followed sequentially by cidofovir.
Smee DF; Bailey KW; Sidwell RW
Antivir Chem Chemother; 2000 Jul; 11(4):303-9. PubMed ID: 10950392
[TBL] [Abstract][Full Text] [Related]
15. Progress in the discovery of compounds inhibiting orthopoxviruses in animal models.
Smee DF
Antivir Chem Chemother; 2008; 19(3):115-24. PubMed ID: 19024628
[TBL] [Abstract][Full Text] [Related]
16. Increased susceptibility of Cantagalo virus to the antiviral effect of ST-246®.
Santos-Fernandes É; Beltrame CO; Byrd CM; Cardwell KB; Schnellrath LC; Medaglia ML; Hruby DE; Jordan R; Damaso CR
Antiviral Res; 2013 Mar; 97(3):301-11. PubMed ID: 23257396
[TBL] [Abstract][Full Text] [Related]
17. Treatment of lethal cowpox virus respiratory infections in mice with 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine and its orally active diacetate ester prodrug.
Smee DF; Bailey KW; Sidwell RW
Antiviral Res; 2002 May; 54(2):113-20. PubMed ID: 12062396
[TBL] [Abstract][Full Text] [Related]
18. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir.
Kern ER; Hartline C; Harden E; Keith K; Rodriguez N; Beadle JR; Hostetler KY
Antimicrob Agents Chemother; 2002 Apr; 46(4):991-5. PubMed ID: 11897580
[TBL] [Abstract][Full Text] [Related]
19. Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections.
Kern ER; Prichard MN; Quenelle DC; Keith KA; Tiwari KN; Maddry JA; Secrist JA
Antimicrob Agents Chemother; 2009 Feb; 53(2):572-9. PubMed ID: 19029322
[TBL] [Abstract][Full Text] [Related]
20. CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infections.
Prichard MN; Kern ER; Hartline CB; Lanier ER; Quenelle DC
Antimicrob Agents Chemother; 2011 Oct; 55(10):4728-34. PubMed ID: 21788472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
